Compare · ALVO vs GILD
ALVO vs GILD
Side-by-side comparison of Alvotech (ALVO) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALVO and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $183.62B, about 95.8x ALVO ($1.92B).
- Over the past year, ALVO is down 40.0% and GILD is up 30.3% - GILD leads by 70.3 points.
- GILD has been more active in the news (14 items in the past 4 weeks vs 8 for ALVO).
- GILD has more recent analyst coverage (25 ratings vs 12 for ALVO).
- Company
- Alvotech
- Gilead Sciences Inc.
- Price
- $4.82-1.73%
- $148.48+0.24%
- Market cap
- $1.92B
- $183.62B
- 1M return
- +36.60%
- +11.87%
- 1Y return
- -39.96%
- +30.33%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 8
- 14
- Recent ratings
- 12
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest ALVO
- Alvotech to present at upcoming investor conferences in September
- BofA Securities initiated coverage on Alvotech with a new price target
- SEC Form 6-K filed by Alvotech
- Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
- SEC Form 6-K filed by Alvotech
- Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
- Evercore ISI initiated coverage on Alvotech
- Alvotech to Report Financial Results for H1 2026
- SEC Form 6-K filed by Alvotech
- Alvotech announces successful closure of FDA inspection of manufacturing facility
Latest GILD
- SEC Form N-PX filed by Gilead Sciences Inc.
- Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
- SEC Form S-3ASR filed by Gilead Sciences Inc.
- SEC Form 10-Q filed by Gilead Sciences Inc.
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results